DRUG TRANSPORT IN THE LIVER - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 399

146. Lau YY, Okochi H, Huang Y, Benet LZ. 2006. Multiple transporters affect the disposition
of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ
systems. J Pharmacol Exp Ther 316(2):762-771.
147. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting
polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X
receptor activation. J Pharmacol Exp Ther 304(1):223-228.
148. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H. 2003.
Multiple transport mechanisms involved in the intestinal absorption and first-pass
extraction of fexofenadine. Clin Pharmacol Ther 74(5):423-436.
149. Schuetz EG, Beck WT, Schuetz JD. 1996. Modulators and substrates of P-glycoprotein
and cytochrome P4503A coordinately up-regulate these proteins in human colon
carcinoma cells. Mol Pharmacol 49(2):311-318.
150. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. 2002. Effect of St John's wort
on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71(6):414-420.
151. Matheny CJ, Ali RY, Yang X, Pollack GM. 2004. Effect of prototypical inducing
agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos
32(9):1008-1014.
152. Synold TW, Dussault I, Forman BM. 2001. The orphan nuclear receptor SXR

coordinately regulates drug metabolism and efflux. Nat Med 7(5):584-590.
153. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. 2002.
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlap-
ping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol
62(3):638-646.
154. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi
M, Sueyoshi T. 2001. The phenobarbital response enhancer module in the human
bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear
receptor CAR. Hepatology 33(5):1232-1238.
155. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. 2002. Organ distribution
of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction
of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther
300(1):97-104.
156. Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2005. The role of transporters in drug
interactions. Eur J Pharm Sci 27(5):501-517.
157. DuBuske LM. 2005. The role of P-glycoprotein and organic anion-transporting

polypeptides in drug interactions. Drug Saf 28(9):789-801.
158. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde
K, Roots I, Neumayer HH, Kuhlmann J. 1999. Increase in cerivastatin systemic exposure
after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Clin Pharmacol Ther 65(3):251-261.
159. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated
hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and
cyclosporin A. J Pharmacol Exp Ther 304(2):610-616.
160. Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H, Sugiyama Y. 2004. In vitro and
in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-
mediated hepatic uptake of cerivastatin in rats. Drug Metab Dispos 32(12):1468-
1475.